| Similar Articles |
|---|
 |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated.   |
The Motley Fool
June 2, 2009
Brian Orelli |
ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies. |
The Motley Fool
December 16, 2003
David Nierengarten |
Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks. |
Pharmaceutical Executive
December 1, 2008
Walter Armstrong |
The New Deals Everything you wanted to know about the year's most important deals, and what to watch for in the future. |
The Motley Fool
February 28, 2011
Brian Orelli |
Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out? |
Pharmaceutical Executive
May 1, 2009 |
The Shakeout When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game. |
The Motley Fool
August 28, 2006
Brian Lawler |
The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks. |
BusinessWeek
November 25, 2009
Arlene Weintraub |
Can Roche Leave Genentech Alone? Now that Roche has acquired the biotech superstar, success will depend on keeping some distance. |
The Motley Fool
April 29, 2011
Brian Orelli |
Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya. |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
The Motley Fool
September 25, 2008
Brian Lawler |
Eli Lilly's Dose of Disclosure The pharmaceutical pledges public reports of its dealings with doctors. |
Pharmaceutical Executive
January 1, 2011 |
The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs |
The Motley Fool
January 25, 2010
Brian Orelli |
No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday. |
The Motley Fool
December 31, 2007
Brian Lawler |
The Biotech Year in Review Following the biotech sector is never dull, and 2007 was no exception to the rule. Let's take a look at the highlights and lowlights of 2007. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
The Motley Fool
June 28, 2010
Luke Timmerman |
Future Biotech Winners Will Help Nurses Clean Up Less (Stuff) It's not enough anymore to prove your drug is safe and effective enough to pass muster with the FDA. Now it's also about proving a drug can generate savings and value for the health care system. |
Chemistry World
March 13, 2009
Sarah Houlton |
Mega mergers sweep pharma industry Just six weeks after Pfizer agreed to buy Wyeth, US pharma companies Merck & Co. and Schering-Plough announced they are to merge. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances. |
Fast Company
February 2009
Elizabeth Svoboda |
Wyeth's Multibillion-dollar Biotech Bet Drugmaker Wyeth bet billions on biotech, transforming its culture and boosting profits. |
The Motley Fool
August 18, 2010
Travers & Greer |
Dendreon's Big Pharma Future Dendreon has had success with its prostate cancer treatment Provenge. What does Provenge's success mean for the future of Dendreon? |
The Motley Fool
June 21, 2011
Alexander Crawford |
Bullish Biotech: 5 Biotech Firms Making Great Strides These five biotech firms have just received great news. Should they be on your watch list? |
The Motley Fool
August 23, 2005
W.D. Crotty |
A Myriad of Revenue Myriad Genetics reports a solid fourth-quarter and fiscal year. Is this high-risk biotech concern worth a look? |
The Motley Fool
October 29, 2007
Brian Lawler |
Amgen Revisited Third-quarter financials fail to impress, but there was good news, too from the biotech leader. |
The Motley Fool
August 21, 2008
Brian Lawler |
PDL BioPharma's Partnership Makes Sense Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer. |
The Motley Fool
April 14, 2009
Brian Orelli |
Sell Dendreon! No, Buy Dendreon! Dendreon, everyone's favorite tiny biotech, just got bigger because of positive phase 3 results for its prostate cancer treatment, Provenge. |
The Motley Fool
March 13, 2008
Brian Lawler |
Dendreon Rolls the Dice The pharmaceutical amends a phase 3 study on its lead prostate cancer drug. |
The Motley Fool
November 16, 2010
Luke Timmerman |
Dendreon Prepares to Take Some Heat Over Cancer Drug Prices Dendreon looking for off-label uses for its prostate cancer drug. |
The Motley Fool
April 13, 2007
Brian Lawler |
Genentech Is Still Healthy The biopharma powerhouse announces its first-quarter financial results. Investors, take note. |
The Motley Fool
December 20, 2007
Brian Orelli |
2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something. |
The Motley Fool
March 11, 2010
Jim Mueller |
Is Medivation a Buy? What is the thinking with regards to Medivation today? It already got a big haircut last week. Is it worth investing in at these lower prices? |
The Motley Fool
October 16, 2007
Brian Lawler |
Questions Surround a Biogen Deal Rumors swirl around Biogen after it publicly announces that it's for sale. Investors, take note. |
The Motley Fool
June 5, 2007
Brian Lawler |
Dendreon Gets Its Funding Dendreon does a financing to secure its near-term future. Investors who fail to pay attention to relative valuations of the different stocks in the development-stage biotech space do so at their own peril. |
The Motley Fool
June 9, 2010
Brian Orelli |
ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology. |
The Motley Fool
June 13, 2007
Billy Fisher |
The Best Drug Stock for 2007 Revisited With half of the season left, anything can happen and no lead is safe -- especially in the biotech/pharmaceutical industry. For now the leader, Endo Pharmaceutical, is head and shoulders above the rest. |
The Motley Fool
January 25, 2007
Charly Travers |
The Best Drug Stock for 2007 Is ... Is anyone surprised that the largest biotech company in the world, Genentech, came out on top? |
The Motley Fool
February 15, 2008
Brian Lawler |
Dendreon's Not-So-New Data Development-stage drugmaker Dendreon releases "new data" on lead cancer drug Provenge; unfortunately, the data wasn't the data that investors are waiting for. |
Pharmaceutical Executive
July 1, 2009
Stan Bernard |
Forget Brand vs. Brand--This is War Increasingly, pharma companies are expanding from brand vs. brand to battle at the franchise, portfolio, and corporate levels. |
Financial Advisor
September 2004
Marla Brill |
A Biotechnology Fund On Sedatives Eaton Vance's Worldwide Health Sciences Fund manager Sam Isaly takes some nail biting out of biotech investing. |
The Motley Fool
April 4, 2007
Brian Lawler |
Novartis Gets Nicked Novartis pulls one of its top-selling drugs from the market. Investors should come to expect drug delays or similar issues popping up from time to time when doing their analysis of large pharmas. |
Pharmaceutical Executive
February 1, 2007
Ben Bonifant et al. |
Driven to License The competition for innovative biotech products is intense, giving rise to an unprecedented diversity of partnering strategies and an equally unprecedented convergence of small-molecule drugs and biologics in company portfolios. Licensings are shaping up as the year's big deal. |
The Motley Fool
April 21, 2011
Brian Orelli |
Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested. |
The Motley Fool
October 29, 2007
Brian Lawler |
World's Scariest Stock: Dendreon Investing in the biotech sector is scary enough for most investors. Dendreon's scary future should makes this stock an under-performer. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA |
Pharmaceutical Executive
December 1, 2011
Ben Comer |
Pharm Exec's 2012 Pipeline Report It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle? |
Pharmaceutical Executive
October 1, 2005
Mark J. Ahn |
It's All Academic: Biotechs Looking to Universities Pharmaceuticals and academic institutions are forming alliances at an increasing rate to exploit the promise of emerging biological insights. |
The Motley Fool
June 30, 2010
Brian Orelli |
Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth? |
